EPO906 (epothilone B): A promising novel microtubule stabilizer

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 6, 2003, Pages 51-55

  Rothermel, John ^b   Wartmann, Markus ^b   Chen, Tianling ^b   Hohneker, John ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPOTHILONE B; FLUOROURACIL; GLYCOPROTEIN P; PACLITAXEL; TAXANE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CARCINOMA; CANCER CELL; CARCINOID; CELL DEATH; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MAXIMUM TOLERATED DOSE; MICROTUBULE; MITOSIS; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVIEW; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; EPOTHILONES; HUMANS; MICROTUBULES;

EID: 0037838495     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00125-8     Document Type: Review

References (22)

1. Graf W, Pahlman L, Bergstrom R, et al: The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 70:559-563, 1994
2. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: A randomized trial. J Clin Oncol 10:904-911, 1992
3. Gerth K, Bedorf N, Hofle G, et al: Epothilones A and B: Antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 49:560-563, 1996
4. Höfle G, Bedorf N, Steinmetz H, et al: Epothilone A and B - Novel 16-membered macrolides with cytotoxic activity: Isolation, crystal structure, and conformation in solution. Angew Chem Int Ed Engl 35:1567-1569, 1996
5. Bollag DM, McQueney PA, Zhu J, et al: Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333, 1995
6. Kowalski RJ, Giannakakou P, Hamel E: Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem 272:2534-2541, 1997
7. Wartmann M, Koppler J, Larigot M, et al: Epothilones A and B accumulate several-hundred fold inside cells. Proc Am Assoc Cancer Res 41:213, 2000 (abstr 1362)
8. Altmann KH, Wartmann M, O'Reilly T: Epothilones and related structures - A new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 1470: M79-M91, 2000
9. Giannakakou P, Sackett DL, Kang YK, et al: Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118-17125, 1997
10. O'Reilly T, Mueller M, Vaxelaire J, et al: Epothilone B (EPO906) possesses broad spectrum antitumor activity in experimental models. Proc Am Assoc Cancer Res 43:791, 2002 (abstr 3923)
11. Altmann K-H, Bold G, Caravatti G, et al: Epothilones and their analogs - Potential new weapons in the fight against cancer. Chimia 54:612-621, 2000
12. Altmann K-H, Wartmann M, O'Reilly T: In vivo activity profile of the microtubule-stabilizing agent epothilone B (EPO906) against. Taxol-resistant colon and epidermoid tumors. Proc Am Assoc Cancer Res 41:214, 2000 (abstr 1368)
13. Brueggen J, Altman K-H, Blum W, et al: Pharmacokinetics of EPO906 (epothilone B) in HCT-15 tumor-bearing athymic mice. Proc Am Assoc Cancer Res 43:212, 2002 (abstr 1064)
14. Calvert PM, O'Neill V, Twelves C, et al: A phase I clinical and pharmacokinetic study of EPO906 (epothilone B), given every three weeks, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 20:108a, 2001 (abstr 429)
15. Calvert P, O'Neill V, Azzabi A, et al: A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumors. Clin Cancer Res 6:4581S, 2000 (abstr 575) (suppl)
16. Rubin EH, Siu LL, Beers S, et al: A phase I and pharmacologic trial of weekly epothilone B in patients with advanced malignancies. Proc Am Soc Clin Oncol 20:68a, 2001 (abstr 270)
17. Rougier P, Mitry E: Current treatment options for advanced colorectal cancer. Semin Oncol 27:30-33, 2000
18. Athanassios A, Murren JR: Clinical use of the camptothecins at year 2000. Principle Practice Oncol Updates 14:1-15, 2000
19. Sumpter K, Cunningham D: Combination chemotherapy and colorectal cancer. Semin Oncol 27:105-111, 2000
20. Vanhoefer U, Harstrick A, Achterrath W, et al: Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 19:1501-1518, 2001
21. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/Ieucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. Proc Am Soc Clin Oncol 21:128a, 2002 (abstr 511)
22. Chou T-C, Zhang X-G, Balog D, et al: Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone N. Proc Natl Acad Sci U S A 95:9642-9647, 1998